Is PT-141 (Bremelanotide) Legal in Maryland?

Federal Legal Status of PT-141 (Bremelanotide)

PT-141 is a federally approved prescription drug in the United States. The FDA granted approval on June 21, 2019, under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women. It is not classified as a controlled substance under the federal Controlled Substances Act, meaning the DEA does not schedule it, and prescribers do not need a separate DEA waiver to prescribe it.

FDA Approval and the NDA Record

The FDA approved bremelanotide under NDA 210557. The agency's approval was based on two Phase 3 randomized controlled trials (RECONNECT studies), in which 1,247 women received bremelanotide 1.75 mg subcutaneous injection and demonstrated statistically significant improvements in satisfying sexual events and sexual desire scores compared with placebo [1]. The FDA label for Vyleesi specifies the approved dose, contraindications (including concurrent use of naltrexone), and the self-injection protocol [2].

Because bremelanotide holds an approved NDA, it sits in a categorically different position from unapproved research peptides. Prescribers are not prescribing an investigational compound. They are prescribing a drug with a defined FDA-reviewed safety and efficacy record.

Compounding: 503A vs. 503B Rules

The distinction between 503A and 503B matters practically for cost and access.

503A pharmacies are traditional compounding pharmacies that prepare patient-specific prescriptions. A 503A pharmacy may compound bremelanotide for an individual patient if a licensed prescriber writes a valid prescription and the compounding is not essentially a copy of the commercially available product without a documented clinical reason [3]. The FDA's guidance on 503A compounding is codified in Section 503A of the Federal Food, Drug, and Cosmetic Act [4].

503B outsourcing facilities may only compound drugs from the FDA's bulk drug substances list for 503B facilities. Bremelanotide is not currently on that list [5]. That means a 503B facility cannot legally produce bremelanotide in bulk without patient-specific orders. Patients and providers should verify that any compounding pharmacy dispensing bremelanotide is operating under 503A rules with a valid prescription in hand.

The FDA's current bulk drug substances list for 503B outsourcing facilities is publicly available and updated periodically [5].

Maryland State Legal Framework

Maryland does not add a separate state-level scheduling layer on top of federal approval for bremelanotide. The drug is not listed on the Maryland Controlled Dangerous Substances (CDS) schedule under the Maryland Code, Health-General Article, Title 5 [6]. This means the state imposes no additional restrictions beyond standard prescription drug rules that apply to any legend drug.

Maryland Board of Pharmacy Rules

The Maryland Board of Pharmacy licenses and regulates pharmacies dispensing prescription drugs in the state [7]. Any pharmacy, retail or compounding, that dispenses bremelanotide to a Maryland patient must hold a current Maryland pharmacy license. A 503A compounding pharmacy licensed in another state may dispense to Maryland patients only if it also holds a non-resident pharmacy permit issued by the Maryland Board of Pharmacy [7].

Before filling a prescription at an out-of-state or online pharmacy, patients should confirm the pharmacy's license status on the Maryland Board of Pharmacy license lookup portal or the NABP database.

Maryland Medical Practice Act and Prescribing Authority

Under the Maryland Medical Practice Act, only practitioners holding a valid Maryland license may prescribe legend drugs to Maryland patients in the context of a legitimate prescriber-patient relationship [8]. Physicians (MD/DO), nurse practitioners, and physician assistants who hold prescriptive authority in Maryland may all legally prescribe bremelanotide, provided the prescribing is within their scope of practice and based on a proper clinical evaluation.

The prescriber is not required to use a special triplicate or duplicate prescription form for bremelanotide because it is not a controlled substance. A standard written, electronic, or faxed prescription is sufficient under Maryland law.

Off-Label Prescribing in Maryland

The FDA approved Vyleesi specifically for premenopausal women with HSDD. Prescribing it off-label for men (PT-141 has been studied in men for erectile dysfunction) or for postmenopausal women is legally permissible under federal and Maryland law. The FDA explicitly states that the agency does not regulate the practice of medicine, and licensed practitioners may prescribe approved drugs for unapproved uses based on clinical judgment [9]. Off-label prescribing does not make the prescription illegal, but it does shift more of the informed-consent burden to the prescriber.

Clinical Background: What PT-141 Actually Does

PT-141 is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Unlike PDE5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, bremelanotide acts centrally through melanocortin receptors (MC1R, MC3R, MC4R) in the hypothalamus to increase sexual motivation and arousal [1].

The RECONNECT Phase 3 Data

The two RECONNECT trials enrolled 1,247 premenopausal women with acquired, generalized HSDD. At 24 weeks, women on bremelanotide 1.75 mg showed a statistically significant increase in the number of satisfying sexual events (SSEs) compared with placebo (least-squares mean difference: 0.7 SSEs per month, P<0.001) [1]. The Female Sexual Function Index desire domain score improved by a least-squares mean of 0.3 points more than placebo (P<0.001) [1]. Roughly 25% of participants in the active arm reported clinically meaningful reductions in distress related to low sexual desire [1].

The most common adverse effects were nausea (40%), flushing (20%), and transient blood pressure increases peaking approximately 12 minutes after injection and resolving within 12 hours [2]. The FDA label carries a warning against use in patients with cardiovascular disease for this reason [2].

Data in Men: Research Context

In men, PT-141 was studied for erectile dysfunction in early Phase 2 trials. A 2004 study by Wessells et al. (N=20) reported that intranasal bremelanotide produced erections in 17 of 20 men with psychogenic erectile dysfunction [10]. Larger trials in men were discontinued after the intranasal formulation caused transient hypertension, but the subcutaneous dose in Vyleesi produces a smaller pressor effect. Off-label use in men remains an area of clinical interest without Phase 3 data in that population [10].

How Maryland Residents Can Access PT-141 Legally

Access requires three things in the correct sequence: a clinical evaluation, a valid prescription, and a licensed dispensing pharmacy. None of these steps can be skipped without entering illegal territory.

Step 1: Clinical Evaluation with a Licensed Maryland Provider

A Maryland-licensed prescriber must evaluate the patient and document a diagnosis (or off-label clinical rationale) before writing a prescription. For HSDD, clinical evaluation typically includes screening tools such as the Female Sexual Distress Scale (FSDS-R) and a review of medications that may contribute to low desire (SSRIs, hormonal contraceptives, antihypertensives) [11].

The evaluation may occur in-person or via telehealth. Maryland law permits telehealth prescribing when a valid prescriber-patient relationship exists [8]. A prescriber must conduct a good-faith evaluation; questionnaire-only or "prescription-from-a-photo" services do not satisfy this requirement.

Step 2: Prescription Issued and Sent to a Licensed Pharmacy

The prescriber sends the prescription to a Maryland-licensed pharmacy or a licensed out-of-state pharmacy with a Maryland non-resident permit. The prescription must specify bremelanotide 1.75 mg/0.4 mL subcutaneous injection. For the brand Vyleesi, the pharmacy dispenses the auto-injector kit. For a 503A compounded version, the prescription may specify the same dose in a multi-dose vial format, provided the pharmacy documents a clinical reason for compounding rather than using the commercially available product [3].

Step 3: Telehealth Platforms Operating Legally in Maryland

Telehealth platforms that offer PT-141 (or Vyleesi) in Maryland must employ or contract with Maryland-licensed prescribers, maintain prescriber-patient relationships that meet Maryland Medical Practice Act standards, and dispense only through licensed pharmacies. Patients should ask any platform three direct questions before purchasing:

1. Is the prescribing clinician licensed in Maryland?
2. Which specific pharmacy will fill the prescription, and does it hold a Maryland pharmacy license or non-resident permit?
3. Is the product the FDA-approved Vyleesi auto-injector, or a 503A-compounded formulation? If compounded, what is the documented clinical reason for not dispensing the commercially available product?

What Is Not Legal in Maryland

Purchasing Without a Prescription

Bremelanotide sold without a prescription is being sold illegally under both federal and Maryland law. No amount of a vendor labeling the product "for research use only" or "not for human consumption" changes this. The FDA has issued warning letters to companies selling peptides, including melanocortin analogs, without approved status or proper labeling [12]. Purchasing from such vendors exposes patients to unverified purity, unknown concentrations, and no physician oversight.

Importing from International Sources

Personal importation of prescription drugs from international sources is generally prohibited under the Federal Food, Drug, and Cosmetic Act. The FDA's personal importation policy allows narrow exceptions for drugs not available in the U.S. And used under a physician's supervision for serious conditions [13]. Bremelanotide does not qualify for this exception because an FDA-approved version exists domestically. Maryland residents importing bremelanotide from overseas vendors are violating federal law.

Gray-Market Peptide Vials

Some vendors sell bremelanotide acetate powder or pre-mixed vials labeled as research chemicals. These products have not been manufactured under FDA current Good Manufacturing Practice (cGMP) standards, have not been tested for sterility or endotoxin burden, and are not legally dispensed for human use [12]. Reconstituting and injecting a non-cGMP peptide carries real infection and dosing risks.

Insurance, Cost, and Practical Considerations

Vyleesi (brand bremelanotide) has limited formulary coverage. The manufacturer's list price has historically been above $800 per single-use auto-injector, though manufacturer copay assistance programs have been available for commercially insured patients [2]. Compounded bremelanotide from a 503A pharmacy is typically less expensive, often ranging from $150 to $350 per multi-dose vial depending on the compounding pharmacy, though patients should confirm the pharmacy's 503A licensure and cGMP compliance.

Prior authorization requirements vary by insurer. Maryland's Medicaid program does not currently list Vyleesi on its preferred drug list, making out-of-pocket payment the practical reality for most Maryland patients accessing this drug [6].

The American College of Obstetricians and Gynecologists (ACOG) published guidance in 2019 noting that both flibanserin and bremelanotide "are approved treatments for HSDD in premenopausal women" and that "clinicians should discuss the modest benefit, known side effects, and cost with patients before prescribing" [11].

Comparison: Bremelanotide vs. Flibanserin for HSDD in Maryland

Both FDA-approved pharmacologic treatments for HSDD in premenopausal women are legally prescribable in Maryland without controlled-substance restrictions. Flibanserin (Addyi) was approved in August 2015 and requires daily oral dosing, while bremelanotide is dosed as-needed subcutaneously [14]. A 2020 network meta-analysis by Jaspers et al. Found that bremelanotide produced a statistically significant improvement in SSEs relative to placebo (standardized mean difference 0.22, 95% CI 0.08-0.35), comparable in magnitude to the effect seen with flibanserin in similar populations [15].

Patients who experienced inadequate response or tolerability issues with flibanserin may be reasonable candidates for bremelanotide, and vice versa. The decision between the two is clinical, not regulatory, in Maryland.

The Endocrine Society's clinical practice guidelines on female sexual dysfunction, updated in 2019, recommend shared decision-making that includes a discussion of both approved pharmacologic and non-pharmacologic options before initiating drug treatment [16].

Key Takeaways for Maryland Patients and Prescribers

PT-141 (bremelanotide, Vyleesi) is a legal prescription drug in Maryland. No special state scheduling, no DEA waiver, and no triplicate prescription are required. The path to legal access runs through a licensed Maryland prescriber, a proper clinical evaluation, and a licensed pharmacy. Compounding is permissible under 503A rules but not through 503B outsourcing facilities. Purchasing from research-chemical vendors or importing from overseas is illegal and poses real safety risks.

Maryland residents should request a telehealth or in-person consultation with a prescriber who documents a clear clinical indication, specifies the correct dose (1.75 mg subcutaneous injection), and routes the prescription to a verifiable licensed pharmacy.